Van De Mierop F, Fleischer D. Endoscopic hemostasis in nonvariceal bleeding: An overview. Endoscopy 1996; 28: 54-65
Rutgeerts P, Rauws E, Wara P et al. Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer. Lancet 1997; 350: 692-696
Berg PL, Barina W, Born P. Endoscopic injection of fibrin glue versus polidocanol in peptic ulcer hemorrhage: A pilot study. Endoscopy 1994; 26: 528-530
Kubba AK, Murphy W, Palmer KR. Endoscopic injection for bleeding peptic ulcer: A comparison of adrenaline alone with adrenaline plus human thrombin. Gastroenterology 1996; 111: 623-628
Chouhan VD, De La Cadena RA, Nagaswami C et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: Effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 1997; 77: 343-349
Knobl P, Lechner K. Acquired factor V inhibitors. Baillière's Clin Haematol 1998; 11: 305-318
Ortel TL, Charles LA, Keller FG et al. Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45: 128-135
Berruyer M, Amiral J, Ffrench P et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations: Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 1993; 105: 892-897
Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients: Report of three cases. J Neurosurg 1993; 78: 817-820
Feinstein DI, Rapaport SI, Chong MM. Factor V inhibitor: Report of a case, with comments on a possible effect of streptomycin. Ann Intern Med 1973; 78: 385-388
Alving BM, Weinstein MJ, Finlayson JS et al. Fibrin sealant: Summary of a conference on characteristics and clinical uses. Transfusion 1995; 35: 783-790
Banninger H, Hardegger T, Tobler A et al. Fibrin glue in surgery: Frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993; 85: 528-532
Ortel TL, Moore KD, Quinn-Allen MA et al. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. Blood 1998; 91: 4188-4196
Chediak J, Ashenhurst JB, Garlick I, Desser RK. Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions. Blood 1980; 56: 835-841
Chiu HC, Rao AK, Beckett C, Colman RW. Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood 1985; 65: 810-818
Tarantino MD, Ross MP, Daniels TM, Nichols WL. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997; 19: 226-231
Fu YX, Kaufman R, Rudolph AE, Collum SE, Blinder MA. Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 1996; 51: 315-318
Tribl B, Knobl P, Derfler K et al. Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression. Ann Hematol 1995; 71: 199-203